Merus Stock Price, News & Analysis

Merus (NASDAQ:MRUS) reported significant Q2 2025 results and clinical progress. Their lead drug petosemtamab with pembrolizumab showed a 63% response rate in 43 evaluable head and neck cancer patients, with 79% overall survival at 12 months. The company successfully completed a $345M public offering, extending cash runway into 2028 with $892M in cash and equivalents.

Two phase 3 trials for petosemtamab in head and neck cancer are expected to be substantially enrolled by YE25, with potential topline interim readouts in 2026. The drug received Breakthrough Therapy Designation from FDA for first-line PD-L1+ HNSCC treatment. Initial clinical data for colorectal cancer is planned for 2H25.

Q2 financials showed increased R&D expenses of $93.9M, up $44.8M year-over-year, primarily due to clinical trial expansion. Revenue increased by $1.5M compared to Q2 2024, driven by collaboration partnerships.

Merus N.V. (NASDAQ: MRUS), an oncology company specializing in multispecific antibody therapeutics, has granted stock options to two new employees as inducement awards. The options, approved on August 1, 2025, allow the purchase of up to 240,000 shares at an exercise price of $65.56 per share.

The options have a ten-year term and vest over four years, with 25% vesting on the first employment anniversary and the remainder vesting monthly over three years. These grants were made outside the Company's 2016 Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Merus N.V. (MRUS) has announced the pricing of a public offering of 5,263,158 common shares at $57.00 per share, aiming to raise approximately $300.0 million in gross proceeds. The company has granted underwriters a 30-day option to purchase up to an additional 789,473 shares. The offering is expected to close around June 5, 2025. Merus plans to use the net proceeds to advance clinical development of its product candidates, fund preclinical research and technology development, and support working capital and general corporate purposes. The offering is being led by multiple joint book-running managers including Jefferies, BofA Securities, Leerink Partners, Guggenheim Securities, Truist Securities, and LifeSci Capital, with Van Lanschot Kempen acting as lead manager.

Merus N.V. (MRUS), an oncology company specializing in multispecific antibodies and antibody drug conjugates, has announced a proposed public offering of common shares. The offering includes a 30-day option for underwriters to purchase up to an additional 15% of shares. The company plans to use the proceeds to advance clinical development of product candidates, fund preclinical research, and support working capital needs. The offering is being managed by multiple firms including Jefferies, BofA Securities, Leerink Partners, Guggenheim Securities, Truist Securities, and LifeSci Capital as joint book-running managers, with Van Lanschot Kempen as lead manager. The offering will be conducted through a shelf registration statement on Form S-3 filed with the SEC.

Merus N.V. (Nasdaq: MRUS), a company specializing in oncology and developing innovative multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), has announced upcoming presentations at two major investor conferences. CEO Bill Lundberg will present at the William Blair 45th Annual Growth Stock Conference on June 3 at 9:40 a.m. ET and the Jefferies Global Healthcare Conference on June 4 at 3:10 p.m. ET. The presentations will be available via webcast on the company's Investors page, with recordings accessible for a limited time afterward.

Merus (NASDAQ: MRUS) announced promising interim data from its phase 2 trial of petosemtamab combined with pembrolizumab for head and neck squamous cell carcinoma (HNSCC). The study showed a 63% response rate among 43 evaluable patients, including 6 complete responses and 21 partial responses. Key highlights include:

- 79% overall survival rate at 12 months - 9 months median progression-free survival - Responses observed across PD-L1 levels - 14 responding patients still on treatment

The treatment combination was generally well-tolerated, with Grade ≥3 treatment-emergent adverse events occurring in 60% of patients. Infusion-related reactions were reported in 38% of patients, mainly during first infusion. The data suggests potential superiority over pembrolizumab monotherapy, positioning petosemtamab as a possible future standard of care in head and neck cancer. Merus expects to share top-line interim readout of phase 3 trials in 2026.

Merus announced the publication of petosemtamab's mechanism of action in the journal "Cancers". Petosemtamab, a bispecific antibody targeting EGFR and LGR5, works through three distinct mechanisms: EGFR ligand blocking, EGFR receptor internalization and degradation in LGR5+ cells, and Fc-mediated immune system activation. The drug has shown significant clinical activity in head and neck squamous cell carcinoma (HNSCC). Phase 3 trials are ongoing in first-line PD-L1+ and second/third-line r/m HNSCC, expected to be substantially enrolled by year end. Additionally, a phase 2 trial is evaluating petosemtamab in metastatic colon cancer (mCRC), with initial clinical data expected in H2 2025.

Merus (Nasdaq: MRUS), a biotechnology company specializing in oncology and the development of multispecific antibodies (Biclonics® and Triclonics®), has announced its participation in the BofA Securities 2025 Health Care Conference. CEO Bill Lundberg will engage in a fireside chat on May 15, 2025, at 8:40 a.m. PT/11:40 a.m. ET. The presentation will be available via webcast on the company's Investors webpage, with a recording accessible for a limited time afterward.

Merus (MRUS) reported Q1 2025 financial results and provided business updates. The company's petosemtamab drug shows promising progress with two phase 3 trials expected to be substantially enrolled by year-end 2025. The company plans to present updated interim phase 2 data for petosemtamab in combination with pembrolizumab at the 2025 ASCO Annual Meeting. Financially, Merus reported $638 million in cash and equivalents, expected to fund operations into 2028. Q1 2025 revenue increased by $18.6 million compared to Q1 2024, primarily due to commercial material revenue. However, operating expenses increased significantly, with R&D expenses up by $41.5 million and G&A expenses up by $6.0 million. The company reported a net loss of $96.47 million for Q1 2025, compared to a $34.46 million loss in Q1 2024.